Loading component...
Loading component...
Loading component...
Loading component...
Connect with our experts to find out more about our analytical testing solutions at this two week virtual event.
Connect with our experts to find out more about our analytical testing solutions at this two week virtual event.
Our experts will participate in the following panel discussions:
Our expert, Gary Chambers, Global Head, Life Sciences at SGS will attend this panel.
With the existence of a wide variety of regulatory approaches in the different knowledge areas, it becomes a priority to encourage regulatory harmonization. As the global market becomes more critical, pharmaceutical companies will require more significant cooperation among national regulators to get life saving products to market faster and minimize issues with regulatory compliance.
Our expert, Houri Simonian, Director, Analytical Operations at SGS will join this roundtable, which will feature a high level panel discussion by industry experts, with numerous opportunities for audience interaction – polls, Q&A and breakout networking sessions. This will provide a great opportunity to deep dive into specific topics, discuss opinions and gather insights from the wider pharma community.
Medicine regulatory authorities first became aware of the presence of the nitrosamine impurity N-nitrosodimethylamine (NDMA) in 2018. Since then, the work towards preventing and managing the presence of nitrosamine impurities in medicines has gained attention. Understanding when and where nitrosamines may become present in drug products has become a growing task for the pharmaceutical industry. A better understanding of the precursors and conditions that trigger their formation might lead the industry to reduce the possibility of nitrosamines appearing in pharmaceutical products, in order to assure the safety of patients and the quality of the final drug substance.
For further information, please contact:
Aurélia Resines
Global Marketing Manager
t: +41 22 739 91 11